TABLE 6.

Susceptibilities of gram-negative bacteria isolated from ICU patients in four European countries, Canada, and the United States to antimicrobials^a

Organism	Antimicrobial agent	France		Germany		Italy		Spain		Canada		United States
		No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible
E. coli	Cefotaxime	6,031	99.0	3,449	98.0	1,105	94.5	1,428	96.6	1,886	96.4	5,745	96.9
	Ceftazidime	5,896	98.1	1,769	98.1	1,525	94.3	1,220	97.2	2,861	97.9	9,412	95.6
	Ceftriaxone	531	98.9	353	99.7	888	93.7	NAb	NA	2,618	97.1	10,182	97.6
	Ciprofloxacin	5,504	93.6	2,695	87.8	1,570	89.5	1,321	81.7	3,197	90.9	11,130	90.6
	Gentamicin	6,104	95.7	2,783	94.5	1,596	93.6	1,469	90.8	4,332	94.3	13,127	92.7
	TMP-SMX	5,841	78.3	3,264	74.7	1,473	77.7	1,476	66.9	4,395	84.9	12,921	79.5
K. pneumoniae	Cefotaxime	1,034	94.2	1,505	92.0	598	80.1	496	84.9	817	98.4	4,081	91.4
	Ceftazidime	1,061	92.2	838	87.6	759	70.1	451	85.6	1,456	98.1	6,295	88.2
	Ceftriaxone	71	85.9	108	98.2	608	79.4	NA	NA	1,216	97.9	6,638	92.1
	Ciprofloxacin	977	89.1	1,331	84.6	799	91.6	475	91.2	1,595	92.4	7,150	90.4
	Gentamicin	1,031	97.9	1,274	89.6	819	81.1	514	79.6	1,857	96.8	8,481	91.4
	TMP-SMX	971	88.3	1,450	78.8	759	84.6	514	84.6	1,877	93.2	8,198	88.7

^aData are cumulative for 2000 to 2001.

^bNA, not available, <50 results were available.